| Section | Provisional content |
|---|---|
| Deliverable: SYCE1-related gametogenic failure (seed-only, retrieval blocked) | No tool-retrieved papers or citable context IDs were available in this session, so this report is seed-only, provisional, and not a fully cited 2023–2024 review. All publication-specific claims require manual verification against the seed PubMed records. |
| Retrieval limitation | Evidence retrieval was blocked: paper searches repeatedly returned zero retrievable papers and zero citable contexts, preventing tool-grounded citation, figure review, and independent confirmation of the seed claims. |
| Executive judgment | **Partially supported (provisional).** The seed evidence is consistent with biallelic or otherwise damaging **SYCE1** variants causing meiotic failure through synaptonemal-complex dysfunction, but confidence is limited because the underlying papers were not retrievable for direct verification in this run. |
| Evidence sources (seed PMIDs with PubMed URLs) | **PMID:25062452** — https://pubmed.ncbi.nlm.nih.gov/25062452/ ; **PMID:32402064** — https://pubmed.ncbi.nlm.nih.gov/32402064/ ; **PMID:34718620** — https://pubmed.ncbi.nlm.nih.gov/34718620/ ; **PMID:35718780** — https://pubmed.ncbi.nlm.nih.gov/35718780/ |
| Evidence matrix synopsis | Seed evidence spans four classes: (1) human familial genetics linking a homozygous nonsense SYCE1 variant to POI/primary amenorrhea; (2) model evidence for absent/reduced SYCE1 and synapsis-related infertility mechanism; (3) in vitro/human cohort evidence that SYCE1 variants disrupt interaction with **SYCP1** and/or **C14ORF39/SIX6OS1**, affecting SC assembly; and (4) human male infertility evidence with SYCE1 CNVs and pachytene-stage arrest on H&E/IF. |
| Clinical spectrum (46,XX vs 46,XY) | **46,XX:** primary ovarian insufficiency / primary amenorrhea. **46,XY:** non-obstructive azoospermia with reported pachytene-stage spermatogenic arrest. Detailed endocrine data (e.g., FSH/AMH), ovarian imaging, follicle depletion, semen parameters, and full biopsy-marker data were not retrievable here. |
| Variant/inheritance | Provisional inheritance model: **autosomal recessive / biallelic**. Seed evidence mentions a **homozygous nonsense variant c.613C>T**, additional damaging variants affecting SYCE1 interactions, and **SYCE1 CNVs** in NOA. Exact zygosity/phasing, family counts, CNV breakpoints, segregation details, and ACMG/ClinVar classifications require manual verification. |
| Mechanistic chain | Provisional chain: **biallelic SYCE1 loss/damaging variant -> reduced or absent SYCE1 -> disrupted interaction with SYCP1 and/or C14ORF39/SIX6OS1 -> synaptonemal-complex central element assembly failure -> homologous chromosome synapsis failure during meiotic prophase I -> pachytene arrest/checkpoint activation -> germ-cell depletion -> 46,XX POI/primary amenorrhea or 46,XY NOA/spermatogenic arrest**. Human support appears strongest for phenotype and arrest endpoints; several intermediate steps likely rely on model or in vitro evidence. |
| Diagnostics/management implications | Provisional practice implications: include **SYCE1** on infertility/POI/NOA gene panels with **CNV detection**; in 46,XY consider semen analysis, endocrine evaluation, and biopsy when clinically indicated; in 46,XX assess ovarian reserve and POI biochemistry. Management likely follows standard care pathways: hormone replacement for POI as indicated, fertility counseling, donor-oocyte discussion for POI, and cautious consideration of micro-TESE/ICSI in NOA if sperm retrieval is feasible. |
| Ontology suggestions | **HPO:** Primary ovarian insufficiency; Primary amenorrhea; Female infertility; Azoospermia; Non-obstructive azoospermia; Spermatogenic arrest; Hypergonadotropic hypogonadism. **GO:** Meiotic cell cycle; Homologous chromosome pairing; Synaptonemal complex assembly; Meiotic recombination; Germ cell apoptotic process. **CL:** Primary oocyte; Spermatocyte; Pachytene spermatocyte; Germ cell. **Treatment/action terms:** Genetic testing; Genetic counseling; Hormone replacement therapy; Fertility preservation; Oocyte cryopreservation; Micro-TESE; ICSI; PGT-M. |
| Knowledge gaps | Major gaps reflect the retrieval block: no full-text verification, no figure/table access, no confirmed hormone values or detailed histology, uncertain CNV zygosity/phasing, and limited ability to distinguish direct human evidence from mouse or in vitro inference. Direct evidence for checkpoint activation or apoptosis in human tissue remains especially uncertain. No newer 2023–2024 studies could be identified or prioritized in this environment. |
| Curator leads | After direct review of the seed PMIDs, consider updating the entry to note: (1) a core mechanism of **meiotic synaptonemal-complex central element assembly defect**; (2) dual-sex phenotype of **46,XX POI/primary amenorrhea** and **46,XY NOA/pachytene arrest**; (3) support for **loss-of-function and CNV** mechanisms; and (4) a partner-interaction mechanism involving **SYCP1** and **C14ORF39/SIX6OS1**. Recommended current status for ticketing: **provisional / partially supported pending full-text verification**. |


*Table: This table provides a paste-ready, seed-only provisional curation report for SYCE1-related gametogenic failure. It summarizes the mechanism, phenotype spectrum, variant classes, and verification needs while clearly documenting that retrieval was blocked and no tool-grounded citations were available.*